Attached files
file | filename |
---|---|
8-K - FORM 8-K - AzurRx BioPharma, Inc. | azrx8k_mar32017.htm |
Exhibit
99.1
NEW
YORK, March 08, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.
(AZRX)
(“AzurRx” or the “Company”) a company
specializing in the development of non-systemic, recombinant
therapies for gastrointestinal diseases today announced the
appointment of Charles J “Chuck” Casamento to the Board
of Directors effective March 3, 2017.
Since
2007 Mr. Casamento has been executive director and principal of The
Sage Group, a health care advisory group. He was president
and CEO of Osteologix from October 2004 until April 2007. Mr.
Casamento was the founder of Questcor Pharmaceuticals where he was
president, CEO and chairman. At Questcor he acquired Acthar,
a product whose sales eventually exceeded $1.0 Billion. At RiboGene
Inc. he was president, CEO and chairman and he was also co-founder,
president and CEO of Indevus (formerly Interneuron
Pharmaceuticals). He has held senior management positions at
Genzyme Corporation, where he was Senior Vice President, American
Hospital Supply, where he was Vice President of Business
Development for the Critical Care division, Johnson & Johnson,
Hoffmann-LaRoche and Sandoz. He holds a bachelor's
degree in Pharmacy from Fordham University and an M.B.A. from Iona
College. He currently sits on the Boards of Directors of
International Stem Cell Corporation and Relmada
Therapeutics.
"I am
delighted to welcome Chuck to the AzurRx Board,” said Thijs
Spoor, CEO of AzurRx BioPharma. “This is a pivotal time
for AzurRx as the company is making significant progress in
developing its non-systemic therapeutics pipeline. Chuck’s
valuable expertise and knowledge of the financial community
combined with his interest in the healthcare sector will help us
achieve our objective of providing better therapies to the global
gastrointestinal patient community.”
"I am
pleased to be working with the AzurRx team,” said Mr.
Casamento, “and look forward to adding my voice and
experience to help AzurRx progress in its goals of bringing
transformational therapies to patients."
About AzurRx BioPharma, Inc.
AzurRx
BioPharma aims to become a leader in developing non-systemic,
recombinant protein therapies for the treatment of gastrointestinal
diseases and related conditions. MS1819 recombinant lipase for
exocrine pancreatic insufficiency is the company’s lead
development program, and additional early stage research is being
conducted for the prevention of hospital-acquired infection. The
company is headquartered in New York, NY, with scientific
operations based in Langlade, France.
Company
website address: www.azurrx.com
Forward-Looking Statements
This press release may contain certain statements relating to
future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the
Company’s belief regarding future events, many of which, by
their nature, are inherently uncertain and outside of the
Company’s control. It is possible that the Company’s
actual results and financial condition may differ, possibly
materially, from the anticipated results and financial condition
indicated in these forward-looking statements. Additional
information concerning the Company and its business, including
factors that potentially could materially affect the
Company’s financial results, are contained in the
Company’s filings with the Securities and Exchange
Commission. All forward-looking statements included in this press
release are made only as of the date of this press release, and we
do not undertake any obligation to publicly update or correct any
forward-looking statements to reflect events or circumstances that
subsequently occur or of which we hereafter become
aware.
For more Information:
AzurRx
BioPharma, Inc.,
760
Parkside Avenue
Suite
304
Brooklyn,
NY 11226
Phone:
(646)-699-7855
info@azurrx.com